The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension
| Autor: | Ana Paula Breda, Bruno Arantes Dias, Milena Suesada, Susana Hoette, Rogério Souza, Andre Hovnanian, Silvia Ribeiro de Souza, Carlos Jardim, Luciana Tamie Kato Morinaga, Caio Julio Cesar dos Santos Fernandes |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pulmonary and Respiratory Medicine
Endothelin Receptor Antagonists medicine.medical_specialty Pulmonary Circulation Combination therapy Hypertension Pulmonary Cardiac index Hemodynamics Walking Critical Care and Intensive Care Medicine Pharmacotherapy Internal medicine polycyclic compounds Medicine Humans Schistosomiasis Familial Primary Pulmonary Hypertension Associated Pulmonary Arterial Hypertension Retrospective Studies business.industry Middle Aged Phosphodiesterase 5 Inhibitors medicine.disease Pulmonary hypertension Surgery Drug Therapy Computer-Assisted ANTICOAGULANTES (EFEITOS ADVERSOS) medicine.anatomical_structure Treatment Outcome Vascular resistance Cardiology Population study Vascular Resistance Cardiology and Cardiovascular Medicine business |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| Popis: | Background Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) may be one of the most prevalent forms of pulmonary arterial hypertension (PAH) worldwide. However, the clinical and hemodynamical response to specific PAH therapy in Sch-PAH is not known. Methods We retrospectively analyzed the charts of all patients with Sch-PAH who initiated specific PAH treatment between June 2003 and June 2010 in a single PAH reference center in Sao Paulo, Brazil. Clinical and hemodynamical data were retrospectively collected and evaluated in two periods: baseline and posttreatment. Results The study population consisted of 12 patients with Sch-PAH. They were treated with phosphodiseterase-5 inhibitors (seven patients), endothelin receptor antagonists (four patients), or combination therapy (one patient). Mean treatment period was 34.9 ± 15.5 months. Patients with Sch-PAH presented significant improvements in terms of functional class, 6-min walk test distance (439 ± 85 to 492 ± 79 m, P = .032), cardiac index (2.66 ± 0.59 to 3.08 ± 0.68 L/min/m 2 , P = .028), and indexed pulmonary vascular resistance (20.7 ± 11.6 to 15.9 ± 9 W/m 2 , P = .038) with the introduction of specific PAH treatment. Conclusions We conclude that specific PAH therapy may be of benefit to patients with Sch-PAH, considering clinical, functional, and hemodynamic parameters. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|